BOSTON SCIENTIFIC CORP (BSX) stock intrinsic value fair value estimate & owner earnings analysis

Boston Scientific makes devices used in minimally invasive procedures: heart-rhythm treatment (the FARAPULSE pulsed field ablation system, launched in the U.S. in early 2024), the WATCHMAN left atrial appendage closure device, the AGENT drug-coated balloon and other coronary, peripheral, endoscopy, urology and neuromodulation products. 2025 sales were $20.1 billion, about 64% in the United States. Earning power. We measure owner earnings as operating cash flow with working-capital swings removed, less stock compensation and the capital spending needed to keep the business where it is (we treat about 4.3 cents of capex per extra dollar of sales as growth spending). On that basis owner earnings were $1.56 billion in 2021, $1.76 billion in 2022, $2.40 billion in 2023, $2.95 billion in 2024 and $3.75 billion in 2025 ($2.51 per share). Adding back the interest paid to lenders ($250 million in 2024, $319 million in 2025) gives the cash the business itself produces before debt. We anchor on the 2024-2025 period, because FARAPULSE's U.S. launch and the Axonics, Silk Road and Bolt acquisitions changed the business in 2024; the median of those two years is about $3.63 billion a year. Earlier years describe a smaller, different mix, and 2018 is distorted by a roughly $1.1 billion IRS settlement. The first half of 2026 supports the level: operating cash flow of $1.82 billion was flat with the first half of 2025, but working capital absorbed about $0.4 billion more, so underlying earnings ran roughly 15-20% ahead. Amortization of acquired technology ($897 million in 2025) is a real wasting asset, and so is the habit of buying growth: acquisition spending over 2016-2025 ($18.6 billion) roughly equalled all owner earnings in the period. We therefore credit only modest organic growth and no growth from future acquisitions, since the cash to pay for them is not deducted anywhere else. Penumbra. In January 2026 the company agreed to buy Penumbra (thrombectomy, Lightning Bolt and Lightning Flash systems; about $1.4 billion of 2025 sales) for $374 a share, roughly $14.5 billion, about 73% in cash funded with roughly $11 billion of cash and new debt and the rest in about 41 million new shares. As of the July 2026 update it was expected to close in the second half of 2026 pending remaining regulatory clearances. We treat it as completed: we add about $0.19 billion a year of Penumbra cash earnings, add the new shares (about 1.52 billion in total) and add the cash consideration to the debt. If the deal fails, the per-share values change little. Debt. At June 30, 2026 borrowings were $12.6 billion against $0.5 billion of cash, after $2.0 billion of share repurchases in the first half. With the Penumbra cash consideration, net debt is about $22.5 billion. Most of the existing notes carry fixed coupons below 6%, which would slightly lower the effective burden; we did not take that credit because the new acquisition debt is priced near current rates. Base case: the business keeps converting its installed base and procedure growth into cash at a pace well below the 27% owner-earnings growth of 2025 and the 10-11% organic sales growth the company now expects for 2026: 6% a year for five years, 4% for the next five, then flat, with research spending (already deducted from earnings) replacing products as they age, as it has for decades. The business is worth about $95 billion, owes about $22.5 billion, leaving about $73 billion, or $48 a share. Bear case: competition in pulsed field ablation from Medtronic and Johnson & Johnson and in appendage closure from Abbott holds growth to about 2% a year, and once in the decade a procedure shutdown of the 2020 kind hits; in 2020 owner earnings fell about 36%, and we model a one-third drop with a two-year recovery, then a slow 2% annual decline after year ten as the franchise loses ground. Even at the trough cash flow covers interest more than twice. The business is worth about $55 billion, owes about $22.5 billion, leaving about $32 billion, or $21 a share. Bull case: FARAPULSE and WATCHMAN, the latter supported by the CHAMPION-AF trial meeting its endpoints, keep compounding: 9% a year for five years, 6% for five, then 2% for another decade before leveling. The business is worth about $129 billion, owes about $22.5 billion, leaving about $106 billion, or $70 a share. Previous estimates for this company were built on a different basis and are not comparable to these figures. What changed in the business since then: the Penumbra purchase adds debt and shares, the company lowered its 2026 organic growth expectation after U.S. electrophysiology and WATCHMAN fell short in the first quarter, and first-half 2026 cash earnings came in stronger than they first appear. Margin of safety price: $25. How sure are we of the earnings level? Fairly sure: it rests on two audited years and is corroborated by the first half of 2026. The plausible worst outcome is not a catastrophe but a squeeze: two strong rivals in ablation, pricing pressure from hospitals and a heavier debt load after Penumbra. A diversified product line across thousands of hospitals, no customer concentration, and earnings that cover interest several times over mean the structure survives that. The things we are most likely to be wrong about are the growth rate and the cost of future acquisitions; if organic growth were only 3% a year for a decade, the shares would be worth about $38. The company pays no dividend, so the return has to come from value growth, which we expect to run around 6% a year in the base case, putting value near $64 in five years. The price assumes a holding period of up to five years; from $25 the base case implies a 20% annual return over that period, and the bear value is about $21. Above that price the return depends on the growth case rather than the earnings already in hand.